Health Care/Hospital

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...

2022-11-03 19:00 1546

Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004

BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mell...

2022-11-03 13:11 1944

Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery

SHANGHAI, Nov. 2, 2022 /PRNewswire/ -- Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first Robot-assisted human clinical trial of biliary stent place...

2022-11-02 13:55 1652

WAT Medical Entrusted By Geely Auto To Develop Neuromodulation Technologies To Improve Travel Experiences

VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- With the foreseeable increase in outdoor travelling in the near future, as well as the ever-expanding prospects of self-driving vehicles that have been reported to increase the incidence of nausea and vomiting, motion sickness is becoming a continuously...

2022-11-02 01:15 2183

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ -- I Peace, Inc. ( https://www.ipeace.com ) announced that the company has agreed to join the California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manuf...

2022-11-02 00:00 2201

Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)

* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...

2022-11-01 22:00 2321

Eyeguard System, the Privacy Filter Specialist, Launched New Wellness & Lifestyle Brand "ANBAC"

Healthy Eyes, Mind, and Body SEOUL, South Korea, Nov. 1, 2022 /PRNewswire/ -- Eyeguard System, a privacy filter manufacturer with 20 years of experience, announced that it will launch "ANBAC", new wellness & lifestyle brand for improving life starting from relived eyes.

2022-11-01 21:00 1717

New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography

–  Researchers used Terumo Health Outcomes' ePRISM® software to calculate safe contrast volume targets and improve overall patient outcomes – SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA [1] demonstrate...

2022-11-01 20:00 1472

CBC Healthcare Infrastructure Platform acquires prime industrial land in Shanghai to develop a high-specifications life science park

* 83.76 mu plot within the Life Science zone of the Qingpu Industrial Park, Shanghai Development to include manufacturing facilities and R&D offices SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CBC Healthcare Infrastructure Platform ("CBC HIP"), the infrastructure arm ofAsia's largest healthcare-de...

2022-11-01 11:00 1872

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior V...

2022-10-31 21:30 2714

Announcement of the Effect of Ginseng and Red Ginseng for Memory Improvement and Suppression of Bone and Muscle Loss

* Effect of improving blood pressure in patients with high blood pressure and diabetes * Announced at the 13th International Symposium on Ginseng 2022 SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Experts who have conducted scientific studies on the effect of ginseng gathered inSeoul from...

2022-10-31 21:08 3164

Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2022-10-31 21:00 2207

Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...

2022-10-31 19:00 2493

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...

2022-10-31 08:40 1736

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...

2022-10-31 05:00 1647

Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022

SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...

2022-10-28 22:30 2889

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...

2022-10-28 21:00 2069

Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit

BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...

2022-10-28 20:30 2339

Novel, Biocompatible UV Light Absorber: WPI-MANA

TSUKUBA, Japan, Oct. 28, 2022  /PRNewswire/ -- An International research team at the International Center for Materials Nanoarchitectonics (WPI-MANA) has developed a biocompatible ultraviolet (UV) light-shielding compound from naturally occurring aqueous iron(III), hereinafter aqua-Fe(III), compl...

2022-10-28 14:00 1633

NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review

Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...

2022-10-28 01:37 2275
1 ... 131132133134135136137 ... 277